Canagliflozin use not linked to increased fracture risk in diabetes Hina Zahid2 Jan 2019 7:28 PM ISTIn a Population-based new-user cohort study researchers have found that Canagliflozin use is not linked to increased risk for fracture. The study has...
Hydroxychloroquine as good as SGLT-2 inhibitors as add on therapy to lower blood sugar Deepanjana Sarkar1 May 2019 8:28 PM ISTHydroxychloroquine is as good as SGLT-2 inhibitors (sodium-glucose transport inhibitors)as an add on treatment for lowering blood sugar and HbA1c in...
Sotagliflozin ok as add on treatment for type 1 diabetes with diabetic ketoacidosis risk Medha Baranwal Baranwal9 May 2019 8:10 PM ISTSotagliflozin is beneficial for patients with type 1 diabetes but has the risk of diabetic ketoacidosis.ITALY: In patients with type 1 diabetes (T1D),...
FDA approves combination drug for better blood sugar control in Diabetes Deepanjana Sarkar10 May 2019 7:05 PM ISTFDA approves combination drug for better blood sugar control in Diabetes.The U.S Food and Administration has approved a combination drug formula...
Empagliflozin gets FDA Fast-Track status for Chronic Heart Failure Treatment Deepanjana Sarkar28 Jun 2019 7:30 PM ISTThe U.S Food and Drug Administration has tagged sodium-glucose co-transporter 2 (SGLT2) inhibitor Empagliflozin with Fast-Tracked designation for the...
Empagliflozin also protects against heart disease in addition to regulating blood sugar, finds study Dr. Kamal Kant Kohli Kohli1 Sept 2019 10:00 AM ISTEmpagliflozin helps regulate blood sugar and can also protect against heart disease, finds new study. The researchers at St. Michael's Hospital in...
Blood sugar: Early addition of SGLT2 inhibitor dapagliflozin helps achieve better goals Medha Baranwal Baranwal4 Sept 2019 9:02 AM ISTBlood sugar: Early addition of SGLT2 inhibitor dapagliflozin helps achieve better goals,according to a recent study.Early dapagliflozin use is...
FDA approves Dapagliflozin to reduce risk of Heart Failure in Diabetes Dr. Kamal Kant Kohli Kohli23 Oct 2019 7:20 PM ISTFood and Drug Administration has approved Dapagliflozin to reduce the risk for Heart Failure Hospitalization in Diabetes.The US Food and Drug...
Oral semaglutide bests empagliflozin in reducing weight and HbA1c in diabetes Medha Baranwal Baranwal1 Nov 2019 8:28 PM ISTDelhi: Oral semaglutide, glucagon-like peptide 1 (GLP-1) analog, outperformed sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin in...
SGLT2 inhibitors reduce risk of heart attack and death: BMJ Deepanjana Sarkar2 Sept 2019 8:28 PM ISTBlood sugar lowering agents SGLT2 inhibitors lower risk of heart attack and death finds a new study.Type 2 diabetes drug, sodium-glucose transport...
Dapagliflozin reduces hospitalisation and CV death risk in heart failure patients: Dapa-HF clinical trial Dr. Kamal Kant Kohli Kohli21 Aug 2019 8:20 PM ISTDapagliflozin an SGLT2 inhibitor reduces hospitalization and CV death risk in heart failure patients with or without diabetes, finds Dapa-HF clinical...
Golden drug SGLT2 Inhibitors may lead to Fournier Gangrene, confirms post marketing review Deepanjana Sarkar19 May 2019 8:20 PM ISTThe sodium-glucose cotransporter-2 (SGLT2) Inhibitors have been in discussion due to its possible association with Fournier Gangrene (FG). It has been...
